CSL Limited (CSL.AX) vs Propanc Biopharma, Inc. (PPCB)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| CSL.AX | PPCB | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Size band | LARGE | NANO |
| Listing | ASX | Nasdaq CM |
| Country | Australia | Australia |
| Theme | pharmaceuticals-large-cap | oncology |
| Price and returns | ||
| Last close | 195.14 AUD | $2.29 |
| Return · 1 week | −0.59% | +622.40% |
| Return · 1 month | +7.27% | +329.32% |
| Return · 3 months | +52.37% | +89.26% |
| Return · year to date | +14.94% | −83.98% |
| Return · 1 year | −6.51% | −93.81% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −12.00% | −94.41% |
| 52-week high | 221.76 AUD | $41.00 |
| 52-week low | 90.00 AUD | $0.25 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $65.73B | $2.89M |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $210.03M | $431.78K |
| Employees | 29,000 | 2 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | 20.64× | — |
| Price to sales | 5.96× | — |
| Price to book | 4.43× | 0.12× |
| Enterprise value to EBITDA | 20.64× | n/a (negative value) |
| Enterprise value to revenue | 6.63× | — |
| PEG ratio | 1.82 | — |
| Earnings per share · trailing | -7.99 | -17.62 |
| Profitability | ||
| Gross margin | 50.81% | — |
| Operating margin | 21.49% | 0.00% |
| Profit margin | −16.33% | — |
| Return on equity | −15.84% | −161.86% |
| Return on assets | 7.26% | −70.14% |
| Growth | ||
| Revenue growth | +5.50% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 66.82 | 5.42 |
| Current ratio | 2.21 | 2.55 |
| Dividend yield | 2.07% | 0.00% |
| Payout ratio | 45.12% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 71.88 | 86.57 |
| ADX · 14 | 44.63 | 17.95 |
| 50-day average | 178.58 AUD | $0.79 |
| 200-day average | 144.07 AUD | $2.57 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 1.88% | 10.30% |
The full CSL.AX analysis
Everything this table leaves out for CSL Limited: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the CSL.AX argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full CSL.AX analysisThe full PPCB analysis
Everything this table leaves out for Propanc Biopharma, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the PPCB argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full PPCB analysis